Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sipcam pacific australia pty. limited - fenpyroximate - unknown - fenpyroximate ungrouped active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sipcam pacific australia pty. limited - fenpyroximate - suspension concentrate - fenpyroximate ungrouped active 50.0 g/l - miticide - apple | pear | delicious | golden delicious | granny smith | gravenstein | jonathon | lady william | legana | red delicious | st - carmine mite | european red mite | red spider mite | spider mite | two-spotted mite | two-spotted spider mite

New Zealand - English - Ministry for Primary Industries

adria new zealand ltd - fenpyroximate - fenpyroximate 50 g/litre - miticide

New Zealand - English - Ministry for Primary Industries

corteva agriscience new zealand limited - fenpyroximate - fenpyroximate 50 g/litre - miticide

New Zealand - English - Ministry for Primary Industries

grosafe chemicals limited - fenpyroximate - fenpyroximate 50 g/litre - miticide

New Zealand - English - Ministry for Primary Industries

shandong rainbow international co., limited - fenpyroximate - fenpyroximate 50 g/litre - miticide

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - diphtheria toxoid protein; meningococcal (serogroup a) polysaccharide (monovalent conjugate); meningococcal (serogroup c) polysaccharide (monovalent conjugate); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate); meningococcal (serogroup y) polysaccharide (monovalent conjugate) - injection, solution - 48 microgram (diptheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio) - diphtheria toxoid protein 48 mcg/dose (0.5 ml) (diphtheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio); meningococcal (serogroup a) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup c) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup y) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml)

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - escitalopram oxalate, quantity: 25.552 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; macrogol 400; hypromellose; microcrystalline cellulose; purified talc; titanium dioxide; colloidal anhydrous silica - treatment of major depression, social anxiety disorder (social phobia), generalised anxiety disorder and obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - escitalopram oxalate, quantity: 12.776 mg (equivalent: escitalopram, qty 10 mg) - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; croscarmellose sodium; titanium dioxide; macrogol 400; colloidal anhydrous silica; microcrystalline cellulose; purified talc - treatment of major depression, social anxiety disorder (social phobia), generalised anxiety disorder and obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - flecainide acetate, quantity: 50 mg - tablet - excipient ingredients: magnesium stearate; silicified microcrystalline cellulose; croscarmellose sodium; maize starch - apo-flecainide is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, apo-flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,apo-flecainide tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.